Today: 7 February 2026
Subscribe
Browse Category

NYSE:NVO News 6 January 2026 - 14 January 2026

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer shares rose 1.4% to $25.51 Wednesday morning, outpacing a broader market decline. CEO Albert Bourla said the company misjudged the cash-pay obesity drug market and plans about 10 Phase 3 obesity trials in 2026. Investors are watching for Feb. 3 results and updates on late-stage trial launches. Pfizer expects no revenue growth before 2029 as it faces major patent expirations.
14 January 2026
·····
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer shares fell 0.8% to $25.27 after CEO Albert Bourla compared the obesity drug cash-pay market to Viagra’s early days. The company, which acquired Metsera for up to $10 billion, aims to start up to 10 Phase 3 trials for Metsera’s GLP-1 drug by end-2026. Eli Lilly and Novo Nordisk shares rose, while Pfizer trails rivals in the obesity market.
13 January 2026
···
Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Copenhagen, January 11, 2026, 23:22 CET — Market closed Novo Nordisk (NOVOb.CO) shares climbed 3% to 381.45 Danish crowns on Friday after Amazon Pharmacy announced it will offer the drugmaker’s Wegovy weight-loss pill through insurance coverage as well as a cash-pay option. The U.S.-listed ADRs (NVO) closed 2.6% higher at $58.81. (Reuters) Novo’s new distribution channel is crucial as the company seeks to steady sentiment following a rough 2025. In July, the stock plunged almost 30% in one day after it lowered its 2025 sales forecast. Since then, investors have been quick to sell on any sign of weakening U.S.
11 January 2026
···
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

New York, Jan 11, 2026, 10:13 EST — Market closed Eli Lilly and Company shares dropped 1.99% on Friday, closing at $1,063.56. The stock heads into Monday’s session under pressure after a volatile week for major pharmaceutical firms. Investors are closely eyeing signs of a pricing battle in the obesity-drug sector after Amazon Pharmacy announced it now stocks Novo Nordisk’s Wegovy pill, available both through insurance and a cash-pay plan starting at $149 a month. Amazon added that eligible customers with commercial insurance might pay as little as $25 for a single month’s supply. The timing is key as the
11 January 2026
······
Amazon stock gets a new Wegovy catalyst — what could move AMZN next week

Amazon stock gets a new Wegovy catalyst — what could move AMZN next week

New York, Jan 11, 2026, 09:36 EST — Market closed. Amazon.com’s online pharmacy has started selling Novo Nordisk’s newly approved Wegovy weight-loss pill, expanding the retailer’s health services just before the next U.S. trading session. On Friday, Amazon shares ended the day 0.44% higher, closing at $247.38. Amazon’s new launch marks its entry into the fast-growing GLP-1 drug market—medicines that promote weight loss by mimicking a hormone that regulates appetite and blood sugar. The move comes as investors hunt for growth avenues outside the company’s mainstays, e-commerce and Amazon Web Services. Macro forces could take center stage in the near
11 January 2026
····
Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

NEW YORK, Jan 9, 2026, 10:58 (EST) CICC initiated coverage on Novo Nordisk’s U.S.-listed American depositary receipt (ADR) — a U.S.-traded certificate that represents shares in a foreign company — with an outperform rating and a $73.50 price target, a Finwire report carried by MarketScreener showed on Friday. Novo’s Copenhagen-listed stock was up about 3%. (MarketScreener) The call lands as Novo tries to widen access to Wegovy in pill form, a key test for the maker of Ozempic after profit warnings and sliding shares last year. Investors have watched Eli Lilly pull ahead in the U.S. obesity market, and any
9 January 2026
·
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

NEW YORK, Jan 9, 2026, 10:12 (EST) Amazon Pharmacy said on Friday it now offers Novo Nordisk’s Wegovy weight-loss pill through insurance plans and a cash-pay option, with uninsured customers paying from $149 a month and some commercially insured customers paying $25 for a one-month supply. Amazon said it will add the pill to its pharmacy kiosks in the coming weeks and is working with telehealth firms including WeightWatchers, Wheel and 9amHealth; Novo has said the pill will also be available through CVS, Costco and other telehealth services such as Ro, LifeMD and GoodRx. The U.S. FDA approved the once-daily
9 January 2026
···
Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

NEW YORK, Jan 9, 2026, 09:35 EST — Regular session Amazon Pharmacy said it now offers Novo Nordisk’s Wegovy pill through insurance plans and a cash-pay option, widening its push into prescription drugs as demand for weight-loss treatments spreads beyond injections. Eligible customers with commercial insurance may pay as little as $25 for a one-month supply, while customers without insurance can buy the pill starting at $149 per month; U.S. regulators approved the 25-milligram semaglutide pill in December, the company said. Amazon.com shares were down 0.7% at $244.58 in early New York trade. The rollout matters because Amazon is trying
9 January 2026
···
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

NEW YORK, Jan 9, 2026, 07:03 EST — Premarket Novo Nordisk’s U.S.-listed shares gained 1.4% to $57.34 in premarket trading on Friday after the company rejected claims involving SaveRxCanada.to, a Canadian online pharmacy platform that says it offers India-sourced Ozempic to U.S. patients. SaveRxCanada.to said the pens start at about $280 each, compared with typical U.S. retail prices of $900 to $1,100. A Novo spokesperson said: “We have no customer or partner relationship with this company/platform, and Ozempic from India has not been provided to them.” (reuters.com) The spat comes at an awkward time for drugmakers, with pricing back in
9 January 2026
···
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

New York, Jan 6, 2026, 10:40 EST — Regular session Novo Nordisk A/S shares listed in New York as ADRs climbed about 4.7% to $57.71 on Tuesday, after touching an intraday high of $58.14. The move extends a rebound sparked by the U.S. rollout of a pill version of Wegovy, a franchise that has become central to how investors value the Danish drugmaker’s growth story. The launch matters now because the obesity market is shifting from a supply-driven boom to a fight over price, convenience and who pays. Novo needs the pill to widen demand without triggering a margin-eroding price
6 January 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

New York, January 6, 2026, 07:27 EST — Premarket Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading on Tuesday, extending gains after the Danish drugmaker began selling its once-daily Wegovy weight-loss pill in the United States. The stock was up at $57.29, compared with a prior close of $55.11. Public The launch lands as investors debate how fast the obesity-drug boom can grow without forcing deeper price cuts. It also puts fresh focus on political pressure in Washington to bring down prices for widely used weight-loss medicines. Novo’s push into pills matters because it aims at patients who
6 January 2026
···
1 2 3 4 5 6

Stock Market Today

Lucid stock jumps 14% as Dow tops 50,000 — what LCID investors watch next week

Lucid stock jumps 14% as Dow tops 50,000 — what LCID investors watch next week

7 February 2026
Lucid Group shares jumped 14% to $10.86 at Friday’s close, recovering from an 8% drop the previous day. The move followed a broad Wall Street rally that lifted high-volatility stocks. Lucid reported fourth-quarter deliveries of 5,345 vehicles and full-year deliveries of 15,841. Investors await Lucid’s Feb. 24 results for updates on cash and demand.
Go toTop